MAPK-IN-8
MAPK-IN-8 is an orally active MAPK inhibitor. MAPK-IN-8 can restore the balance of gut microbiota, inhibit M1 macrophage polarization and suppress MAPK mediated inflammation. MAPK-IN-8 can be used in ulcerative colitis research.
For research use only. We do not sell to patients.
- Formula: C15H18BrN3OS
- Molecular Weight:368.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
p38 |
iNOS |
COX-2 |
ERK |
IL-6 |
TNF-α |
Claudin-1 |
JNK |
In Vitro
MAPK-IN-8 (compound 20) (20 µM; 24 h) exhibits no significant toxicity toward RAW 264.7 cells[1].
MAPK-IN-8 (20 µM; pretreatment for 4 h + co-incubation with LPS (HY-D1056) (100 ng/mL for 12 h) significantly inhibits nitric oxide (NO) production in RAW 264.7 cells with an inhibition rate of 67.64%. MAPK-IN-8 significantly downregulates the protein and mRNA expression levels of LPS-induced inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in RAW 264.7 cells. MAPK-IN-8 reduces the secretion of the pro-inflammatory cytokines TNF-α and IL-6 [1].
MAPK-IN-8 (20 µM; pretreatment for 4 h + co-incubation with LPS (100 ng/mL) + IFN-γ (20 ng/mL) for 12 h) modulates macrophage polarization in RAW 264.7 cells. MAPK-IN-8 almost completely blocks polarization toward pro-inflammatory M1 macrophages while actively promoting polarization toward anti-inflammatory M2 macrophages[1].
MAPK-IN-8 (5-20 µM; pretreatment for 4 h + co-incubation with LPS (100 ng/mL for 12 h) inhibits the overactivation of the MAPK signaling pathway in RAW 264.7 cells. MAPK-IN-8 significantly reduces the phosphorylation levels of key components of the MAPK cascade (p38, JNK and ERK) in a dose-dependent manner[1].
MAPK-IN-8 (20 µM; pretreatment for 4 h + co-incubation with exposure to macrophage-conditioned medium for 16 h) significantly protects Caco2 intestinal epithelial cells against the degradation and disruption of tight junction proteins (ZO-1, Occludin, Claudin-4) induced by inflammatory mediators[1].
MAPK-IN-8 (> 128 µg/mL) does not exhibit direct antibacterial activity against various Gram-negative pathogenic bacteria (Escherichia coli, Salmonella typhimurium, Klebsiella pneumoniae and Acinetobacter baumannii) (MIC > 128 µg/mL)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW 264.7 cells
-
Concentration:20 µM
-
Incubation Time:Pretreatment for 4 h + co-incubation with LPS (100 ng/mL) for 12 h
-
Result:Significantly downregulated NO, iNOS and COX-2 protein levels in RAW 264.7 cells.
-
Cell Line:RAW 264.7 cells
-
Concentration:20 µM
-
Incubation Time:24 h
-
Result:Showed no obvious toxicity to RAW 264.7 cells.
-
Cell Line:RAW 264.7 cells
-
Concentration:20 µM
-
Incubation Time:Pretreatment for 4 h + co-incubation with LPS (100 ng/mL) for 12 h
-
Result:Significantly downregulated iNOS and COX-2 mRNA levels in RAW 264.7 cells.
-
Cell Line:RAW 264.7 cells
-
Concentration:20 µM
-
Incubation Time:Pretreatment for 4 h + co-incubation with LPS (100 ng/mL) for 12 h
-
Result:Reduced the secretion of the pro-inflammatory cytokines TNF-α and IL-6.
-
Cell Line:RAW 264.7 cells
-
Concentration:5 µM, 10 µM, 20 µM
-
Incubation Time:Pretreatment for 4 h + co-incubation with LPS (100 ng/mL) for 12 h
-
Result:Significantly reduced the phosphorylation levels of key components of the MAPK cascade (p38, JNK and ERK) in a dose-dependent manner.
-
Cell Line:Caco2 cells
-
Concentration:20 µM
-
Incubation Time:Pretreatment for 4 h + co-incubation with exposure to macrophage-conditioned medium for 16 h
-
Result:Inhibited the degradation and disruption of tight junction proteins (ZO-1, Occludin, Claudin-4) in Caco2 cells.
In Vivo
MAPK-IN-8 (200 mg/kg or 300 mg/kg; i.g.; once daily; for 3 days) shows excellent gastrointestinal safety in fasted male Wistar rat models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (7-weeks-old, female) were fed with 2% DSS for 7 days[1].
-
Dosage:10 mg/kg
-
Administration:i.g.; once daily; for 7 days
-
Result:Significantly ameliorated weight loss, colon shortening and disease activity index (DAI) scores.
Protected and maintained the expression of intestinal epithelial tight junction proteins (ZO-1, Occludin, Claudin-4).
Significantly suppressed the accumulation of M1 macrophages in the colon and spleen and the production of pro-inflammatory mediators (INOS, TNF-α, IL-6 and MPO) in vivo.
Inhibited the phosphorylation of MAPK signaling pathways (ERK, JNK and p38).
Reshaped the disrupted gut microbiota.
Showed no apparent toxic side effects on major organs such as the heart, liver, spleen, lungs and kidneys.
-
Animal Model:Wistar rats (220-270 g, male) were fasted for 18 h[1].
-
Dosage:10 mg/kg
-
Administration:i.g.; once daily; for 3 days
-
Result:Did not induce severe ulcers larger than 3 mm, and compared to the corresponding doses of IBU, its ulcer index (UI) was reduced by 90.3% and 78.4%.
Exhibited no significant inhibitory effect on COX-1 protein expression in the gastric mucosa, thereby avoiding the severe depletion of protective prostaglandin E2 (PGE2).
Chemical Information
-
Molecular Weight 368.29
-
Formula C15H18BrN3OS
-
SMILES
CC(C1=CC=C(CC(C)C)C=C1)C(NC2=NN=C(Br)S2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Microbiome Analysis
Microbiome analysis characterizes microbial communities in biological or environmental samples by measuring community composition, diversity, taxonomic structure, functional potential, and associations with host or environmental phenotypes. 16S rRNA gene amplicon sequencing is commonly used for bacterial and archaeal taxonomic profiling, while shotgun metagenomics provides higher taxonomic resolution and direct functional information, including microbial genes, pathways, viruses, fungi, and antimicrobial-resistance genes when sequencing depth and host-DNA contamination are adequately controlled. Microbiome results are strongly affected by sample collection, storage, DNA extraction, contamination, sequencing method, reference database, and bioinformatic pipeline; therefore, standardized protocols, negative controls, mock communities, and transparent analysis workflows are required. Unresolved issues include low-biomass contamination, compositional-data bias, inconsistent species-level c
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)